Name Contact Info Research Interests
James Moon James Moon
John G. Searle Associate Professor of Pharmaceutical Sciences, College of Pharmacy, and Associate Professor of Biomedical Engineering, College of Engineering
734/763-0911
moonjj@umich.edu
B10 Rm A190
  • Nanotechnology

    Biomaterials

View more
Carlos Rodriguez
LEO Intermittent Lecturer
734/615-3749
carodrig@umich.edu
2002 Pharm
Nair Rodriguez-Hornedo Nair Rodriguez-Hornedo
Professor of Pharmaeceutical Sciences
734/763-0101
nrh@umich.edu
3567 NUB
Gustavo Rosania Gustavo Rosania
Professor of Pharmaceutical Sciences
734/763-1032
grosania@umich.edu
3062 Pharm
  • Exploring the application of in silico models, such as the cell-based molecular transport simulations we use in our experiments, to pharmaceutical discovery and development

    Exploring cell-based molecular transport simulations as a way to probe the role of microscopic drug transport as a determinant of drug absorption, distribution, metabolism, and excretion

View more
Anna Schwendeman Anna Schwendeman
Associate Professor of Pharmaceutical Sciences
734/763-4056
annaschw@umich.edu
B20 Rm 102W
  • Rational design of novel synthetic HDL nanomedicines for treatment of atherosclerosis by designing new ApoA-I mimic peptides and optimizing phospholipid composition

    Therapeutic applications of HDL nanomedicines for treatment of Alzheimer’s disease, septic shock, acute lung injury, lupus and diabetic nephropathy

View more
Steven Schwendeman Steven Schwendeman
Chair and Ara G. Paul Professor of Pharmaceutical Sciences, College of Pharmacy, and Professor of Biomedical Engineering, College of Engineering
734/615-6574
schwende@umich.edu
B20 Rm 102W
  • Physical and chemical stability of microencapsulated bioactive agents. We examine the underlying molecular mechanisms responsible for the instability of substances, particularly proteins and other biomacromolecules, when encapsulated in the most commonly used material for controlled release, copolymers derived from lactic and glycolic acids (PLGA) and related biodegradable polymers.

    Microencapsulation of biomacromolecules. We examine the underlying molecular mechanisms that govern microencapsulation, particularly for process-sensitive biomacromolecules. Through our mechanistic findings related to polymer/drug behavior in other projects, we have devised two new approaches for facile microencapsulation of biomacromolecular therapeutics with strong advantages over existing methods. These new methods will be published shortly and related patents are pending.

View more
Satish Singh
Adjunct Professor
ssatish@umich.edu
2002 Pharm
David Smith David Smith
John G. Wagner Collegiate Professor of Pharmacy
734/647-1431
smithb@umich.edu
4008 Pharm
  • Pharmacokinetics and biopharmaceutics

    Drug transport mechanisms and transporters

View more
Sejin Son
Assistant Research Scientist
734/763-7118
ssejin@umich.edu
B020-326W
Duxin Sun Duxin Sun
J. G. Searle Professor of Pharmaceutical Sciences, College of Pharmacy
734/615-8740
duxins@umich.edu
B520 Rm 3353
  • Breast Cancer Stem Cells and Therapeutics

    The goal of this project is to visualize the cancer stem cells hierarchy to answer questions for how heterogeneous breast cancer cells are generated by breast cancer stem cells? How chemotherapy alters heterogeneity by changing breast cancer stem cells? Why chemotherapy can not “cure” cancer? How to identify drugs or targets to eliminate different populations of heterogeneous cancer cells in order to “cure” cancer.

    Drug Discovery to Treat P53/PTEN Deficient Triple Negative Breast Cancer

    Among four types of breast cancers, triple negative breast cancer (TNBC) still lacks treatment options. Triple negative breast cancer (TNBC) exhibits high frequencies of p53 and PTEN genetic aberrations, with 84% and 35%, respectively, which is associated with metastasis, low therapeutic response, and poor prognosis. However, the concurrent p53/PTEN deficiency in TNBC is not actionable due to the lack of molecular targets. The goal of this project is to identify specific therapeutic target for drug discovery to treat P53/PTEN deficient TNBC.

View more

Pages